leadf
logo-loader
viewAstraZeneca

AstraZeneca pushes back timeline for MYSTIC phase III lung cancer clinical trial

Based on current predictions, the final analysis of overall survival data from the phase III study is expected in the second-half of the year rather than the first

1520839966_lungs.jpg
The open-label efficacy assessment was designed to test the combination therapy against the current gold standard chemotherapy for patients with a form of locally-advanced or metastatic non-small cell lung cancer

AstraZeneca PLC (LON:AZN) said the timeline for its closely-followed MYSTIC clinical trial, treating patients with late-stage lung cancer has been pushed back.

Based on current predictions, the final analysis of overall survival data from the phase III study is expected in the second-half of the year rather than the first.

MYSTIC deployed Imfinzi, developed by AZ’s US biotechnology arm MedImmune, in combination with tremelimumab, an antibody treatment also created by the company’s American research arm.

The open-label efficacy assessment was designed to test the combination therapy against the current gold standard chemotherapy for patients with a form of locally-advanced or metastatic non-small cell lung cancer.

The trial is being conducted in 167 centres across 17 countries, including the US, Canada, Europe, and parts of Asia.

Quick facts: AstraZeneca

Price: 8812 GBX

LSE:AZN
Market: LSE
Market Cap: £115.64 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Litigation Capital Management reports 'tremendous growth in overall...

Litigation Capital Management Limited’s (LON:LIT) Patrick Moloney and Nick Rowles-Davies talk to Proactive London about their 'overall good results in a disruptive year'. Some of the operational highlights include the launch of the asset management division following close of US$150m Global...

12 hours, 54 minutes ago

2 min read